Home › Research › Brain tissue and pathology
Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M.. Expert opinion on investigational drugs, 2017-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction There are dozens of drugs in development for AD with billions of dollars invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes. Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug.
What this study adds
Evidence grade: Low
This review examines why Alzheimer's disease drug trials keep failing, noting that there have been more setbacks and failures than treatment successes. The classes of drugs that have failed include monoclonal antibodies, gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mehta, D., Jackson, R., Paul, G., Shi, J., & Sabbagh, M. (2017). Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2017.1323868
Vancouver
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert opinion on investigational drugs. 2017. doi:10.1080/13543784.2017.1323868. PMID: 28460541.
BibTeX
@article{mehta2017-28460541,
author = {Mehta, D. and Jackson, R. and Paul, G. and Shi, J. and Sabbagh, M.},
title = {{Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015}},
journal = {Expert opinion on investigational drugs},
year = {2017},
doi = {10.1080/13543784.2017.1323868},
pmid = {28460541},
url = {https://doi.org/10.1080/13543784.2017.1323868}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Despite the massive investment in AD drugs and a burgeoning pipeline, there have been more setbacks and failures than treatment successes.
- Areas covered: The classes of drugs that have failed to date include the monoclonal antibodies, the gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug.
- Data for these compounds were sought through a PubMed search and a clinicaltrials.gov search.
- Expert opinion: The obvious question to be posed is: Why are they failing?
Why it matters
This review examines why Alzheimer's disease drug trials keep failing, noting that there have been more setbacks and failures than treatment successes. The classes of drugs that have failed include monoclonal antibodies, gamma secretase inhibitors, dimebon, neurochemical enhancers, and one tau drug.
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert opinion on investigational drugs) |
| Journal's citation record | 1 / 4 | Expert Opinion on Investigational Drugs: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 609 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 55.4 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 5 / 6 | Cited 37.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 3 / 4 | Cited 104 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marwan Noel Sabbagh: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Barrow Neurological Institute: institution h-index 384 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28460541) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1080/13543784.2017.1323868
- PubMed: 28460541
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain tissue and pathology from nearby years
Also in Brain tissue and pathology
124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.